Etanercept: An overview

被引：149

作者：

Goffe, B

Cather, JC

机构：

[1] Univ Washington, Dept Dermatol, Seattle, WA 98104 USA

[2] Texas Dermatol Associates, Dallas, TX USA

[3] Baylor Univ, Med Ctr, Dallas, TX USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2003年 / 49卷 / 02期

关键词：

D O I：

10.1016/mjd.2003.554

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Etanercept, a competitive inhibitor of TNF-alpha, is currently FDA approved for psoriatic arthritis and rheumatoid arthritis. The molecular structure of etanercept, its mechanism of action, and results of clinical trials involving patients with psoriasis will be reviewed.

引用

页码：S105 / S111

页数：7

共 29 条

[1] STABILIZATION OF THE BIOACTIVITY OF TUMOR-NECROSIS-FACTOR BY ITS SOLUBLE RECEPTORS
ADERKA, D
ENGELMANN, H
MAOR, Y
BRAKEBUSCH, C
WALLACH, D
[J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 175 (02) : 323 - 329
[2] Baugh J A, 2001, Curr Opin Drug Discov Devel, V4, P635
[3] Etanercept-induced subacute cutaneous lupus erythematosus
Bleumink, GS
ter Borg, EJ
Ramselaar, CG
Stricker, BHC
[J]. RHEUMATOLOGY, 2001, 40 (11) : 1317 - 1319
[4] Cytokines in psoriasis
Bonifati, C
Ameglio, F
[J]. INTERNATIONAL JOURNAL OF DERMATOLOGY, 1999, 38 (04) : 241 - 251
[5] CORRELATED INCREASES OF TUMOR-NECROSIS-FACTOR-ALPHA, INTERLEUKIN-6 AND GRANULOCYTE-MONOCYTE COLONY-STIMULATING FACTOR LEVELS IN SUCTION BLISTER FLUIDS AND SERA OF PSORIATIC PATIENTS - RELATIONSHIPS WITH DISEASE SEVERITY
BONIFATI, C
CARDUCCI, M
FEI, PC
TRENTO, E
SACERDOTI, G
FAZIO, M
AMEGLIO, F
[J]. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1994, 19 (05) : 383 - 387
[6] CIMA MA, 2001, ARTHRITIS RHEUM S9, V43, pS403
[7] Cohen MR, 1999, J RHEUMATOL, V26, P1752
[8] ELEVATED TUMOR-NECROSIS-FACTOR-ALPHA (TNF-ALPHA) BIOLOGICAL-ACTIVITY IN PSORIATIC SKIN-LESIONS
ETTEHADI, P
GREAVES, MW
WALLACH, D
ADERKA, D
CAMP, RDR
[J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1994, 96 (01) : 146 - 151
[9] FOERDER CA, EULAR 2002
[10] GASPARI A, 2003, IN PRESS J INVESTIGA

← 1 2 3 →